The current study in humanized E3L.CETP mice demonstrates that GIPR and GLP1R agonism additively attenuate hepatic steatosis, lower inflammation and ameliorate liver injury in the context of HFHC diet-induced NAFLD development. The gene discussed is CETP; the disease is fatty liver disease.